Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial

Rodney Dawson, Andreas H Diacon, Ebrahim Variava, Tumelo Moloantoa, William Brumskine, Tlhago Ngwanto, Ntokozo Zuma-Gwala, Ayman Osman, Mohammed Rassool, Jaclyn Ann Bennet, Yongge Liu, Raymond Xu, Wei Li, Simbarashe Takuva, Jeffrey Hafkin

Open source

DOI: 10.1016/s1473-3099(26)00143-x
Published: 2026-10
Container: The Lancet Infectious Diseases
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1473-3099-26-00143-x,
  title = {Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial},
  author = {Rodney Dawson and Andreas H Diacon and Ebrahim Variava and Tumelo Moloantoa and William Brumskine and Tlhago Ngwanto and Ntokozo Zuma-Gwala and Ayman Osman and Mohammed Rassool and Jaclyn Ann Bennet and Yongge Liu and Raymond Xu and Wei Li and Simbarashe Takuva and Jeffrey Hafkin},
  year = {2026},
  journal = {The Lancet Infectious Diseases},
  doi = {10.1016/s1473-3099(26)00143-x},
  url = {https://doi.org/10.1016/s1473-3099(26)00143-x}
}

RIS

TY  - JOUR
TI  - Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial
AU  - Rodney Dawson
AU  - Andreas H Diacon
AU  - Ebrahim Variava
AU  - Tumelo Moloantoa
AU  - William Brumskine
AU  - Tlhago Ngwanto
AU  - Ntokozo Zuma-Gwala
AU  - Ayman Osman
AU  - Mohammed Rassool
AU  - Jaclyn Ann Bennet
AU  - Yongge Liu
AU  - Raymond Xu
AU  - Wei Li
AU  - Simbarashe Takuva
AU  - Jeffrey Hafkin
PY  - 2026
JO  - The Lancet Infectious Diseases
DO  - 10.1016/s1473-3099(26)00143-x
UR  - https://doi.org/10.1016/s1473-3099(26)00143-x
ER  -

APA

Dawson, R., Diacon, A. H., Variava, E., Moloantoa, T., Brumskine, W., Ngwanto, T., Zuma-Gwala, N., Osman, A., Rassool, M., Bennet, J. A., Liu, Y., Xu, R., Li, W., Takuva, S., & Hafkin, J. (2026). Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(26)00143-x

Source records

crossref · retrieved 2026-09-26T04:30:19.342Z